Drug intelligence / Profile preview

pregabalin + celecoxib

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

Pregabalin + celecoxib is a fixed-dose combination of two small molecule drugs used primarily for the management of pain, particularly in conditions involving both neuropathic and nociceptive mechanisms such as chronic low-back pain, acute postoperative pain, and lumbar disc herniation. Pregabalin is an anticonvulsant that binds to the alpha2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system, thereby reducing the release of excitatory neurotransmitters like glutamate, norepinephrine, substance P, and dopamine. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that reduces inflammation and pain by inhibiting prostaglandin synthesis. The combination has demonstrated superior analgesic efficacy compared to either drug alone and can reduce opioid requirements postoperatively with similar rates of adverse effects as monotherapy[1][2][4][7].

Brand names
LyricaCelebrex
Other names
celecoxib and pregabalinpreemptive celecoxib and pregabalin
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)

Beyond the preview

Go deeper on pregabalin + celecoxib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pregabalin + celecoxib.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call